The FDA granted priority review to perioperative durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive disease, based on phase 3 VOLGA data.
|Poll|December 21, 2012
Soft-Tissue Mass in Left Forearm of 38-Year-Old Man
Author(s)Cesar A. Moran, MD
Advertisement
A 38-year-old man presents with a history of pain and swelling in the left forearm. Physical examination shows the presence of a soft-tissue mass. Surgical resection is performed.
What is your diagnosis?
Advertisement
Related to this article
Longer follow-up is needed for the phase 3 MIDAS trial to determine the impact of MRD conversion on progression-free survival and overall survival.
The FDA cleared TriSalus’s TriNav Advance device, which extends the SmartValve-based drug delivery technology to improve tumor penetration during liver embolization.
In the phase 1b CAMMA 1 trial, cevostamab plus pomalidomide and dexamethasone produced overall response rates of 86.2% to 88.0%.
Data from the phase 3 LITESPARK-011 trial support the FDA approval of belzutifan plus lenvatinib for adults with advanced clear cell renal cell carcinoma.
In the phase 1b portion of the MELT-MM trial, elranatamab plus mezigdomide produced a 100% overall response rate in relapsed/refractory multiple myeloma.
Xiuning Le, MD, PhD, discusses the confirmatory SOHO-02 trial needed to convert sevabertinib’s accelerated approval to full approval.
A pooled analysis of the AMY2009 and AMY3001 trials showed daratumumab plus VCd yielded hematologic complete responses in cardiac-involved AL amyloidosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Belzutifan Combo Receives FDA Approval in Advanced Clear Cell RCC
2
Daratumumab Combo Yields Responses in Cardiac-Involved AL Amyloidosis Trials
3
SOHO-02 Trial Will Confirm Sevabertinib’s Frontline NSCLC Benefit
4
Epcoritamab Combo Receives Canadian Approval in R/R Follicular Lymphoma
5